ao link
Who's Who Legal
Who's Who Legal
Menu

Global Leader

WWL Ranking: Recommended

WWL says

David Lam is an established name in the US life sciences market, whom peers recommended for his expertise and experience with M&A, securities and private equity transactions. 

Biography

David K Lam is a corporate partner at Wachtell, Lipton, Rosen & Katz. He focuses on mergers and acquisitions, securities transactions and corporate governance. His practice has included a wide range of matters, including public and private acquisitions and divestitures, domestic and international transactions, carve-out IPOs, spin-offs, split-offs, joint venture transactions and private equity transactions. He also advises numerous companies on takeover defences, proxy contests and corporate governance matters.

David was selected by The American Lawyer as a “Dealmaker of the Year” for 2012 and also for 2015, and by AmLaw Daily as a “Dealmaker of the Week” in 2015. He is also listed as a “Super Lawyer” in the area of mergers and acquisitions by Super Lawyers magazine. David is a frequent speaker at professional conferences, serving as co-chair of the American Law Institute CLE’s corporate mergers and acquisitions programme in New York.

David received his BA (economics and molecular biophysics and biochemistry) summa cum laude from Yale University, where he was awarded the Arthur Twining Hadley Prize and Russell Henry Chittenden Prize for the highest GPA. He received his JD from Yale Law School, where he served as managing editor of the Yale Law Journal and articles editor of the Yale Journal on Regulation. Upon graduation from law school, Mr Lam served as a law clerk to the Honorable José A Cabranes of the US Court of Appeals for the Second Circuit.

In the healthcare/pharmaceuticals sector he has represented: Abbott Laboratories in its US$25 billion acquisition of St. Jude Medical, its US$4.3 billion sale of its vision care business to Johnson & Johnson and its US$55 billion spin-off of AbbVie; Pfizer in its agreed US$160 billion acquisition of Allergan plc and in its US$5.2 billion acquisition of Anacor Pharmaceuticals; and AbbVie in its US$21 billion acquisition of Pharmacyclics.

In the energy sector he has represented: Seventy Seven Energy Inc in its US$2.1 billion sale to Patterson-UTI Energy; Energy Transfer Equity in its agreed US$37.7 billion combination with The Williams Companies; and Atlas Pipeline Partners and Atlas Energy in their US$7.7 billion sale to Targa Resources Partners and Targa Resources Corp.

In the financial services sector he has represented: Nasdaq in its US$1.1 billion acquisition of International Securities Exchange from Deutsche Börse; BGC Partners in its successful hostile acquisition of GFI Group, its US$650 million sale of Trayport to Intercontinental Exchange, its US$1.234 billion sale of its electronic trading business in US Treasury securities to The NASDAQ OMX Group, Inc and in its US$1.4 billion reorganisation and merger with eSpeed.

In the industrial sector he has represented: Johnson Controls in its US$16.5 billion merger with Tyco International, its spin-off of Adient, its automotive business, its US$1.48 billion sale of its global workplace solutions business to CBRE Group, and its US$965 million sale of its automotive electronics business to Gentex and Visteon; and Rayonier in its spin-off of its performance fibres business.

In the real estate sector he has represented: Washington Prime Group in its US$4.3 billion acquisition of Glimcher Realty Trust; and AMB Property Corporation in its US$15 billion merger with ProLogis.

Law Business Research
Law Business Research Ltd
Meridian House, 34-35 Farringdon Street
London EC4A 4HL, UK
© Law Business Research Ltd 1998-2021. All rights reserved.
Company No.: 03281866